412 related articles for article (PubMed ID: 26433852)
1. Practical Management of CD30⁺ Lymphoproliferative Disorders.
Hughey LC
Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
[TBL] [Abstract][Full Text] [Related]
2. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous CD30(+) lymphoproliferative disorders.
Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
[TBL] [Abstract][Full Text] [Related]
4. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854
[TBL] [Abstract][Full Text] [Related]
5. [Primary cutaneous CD30+ lymphoproliferative disorders].
Calzado-Villarreal L; Polo-Rodríguez I; Ortiz-Romero PL
Actas Dermosifiliogr; 2010 Mar; 101(2):119-28. PubMed ID: 20223154
[TBL] [Abstract][Full Text] [Related]
6. Lymphomatoid Papulosis and Other Lymphoma-Like Diseases.
Moy A; Sun J; Ma S; Seminario-Vidal L
Dermatol Clin; 2019 Oct; 37(4):471-482. PubMed ID: 31466587
[TBL] [Abstract][Full Text] [Related]
7. Large cell transformation mimicking regional lymphomatoid papulosis in a patient with mycosis fungoides.
Nakahigashi K; Ishida Y; Matsumura Y; Kore-Eda S; Ohmori K; Fujimoto M; Yamashita K; Kotani H; Sakurai T; Miyachi Y
J Dermatol; 2008 May; 35(5):283-8. PubMed ID: 18477228
[TBL] [Abstract][Full Text] [Related]
8. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
[TBL] [Abstract][Full Text] [Related]
9. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
[TBL] [Abstract][Full Text] [Related]
10. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Pfaltz K; Vermeer MH; Cozzio A; Ortiz-Romero PL; Bagot M; Olsen E; Kim YH; Dummer R; Pimpinelli N; Whittaker S; Hodak E; Cerroni L; Berti E; Horwitz S; Prince HM; Guitart J; Estrach T; Sanches JA; Duvic M; Ranki A; Dreno B; Ostheeren-Michaelis S; Knobler R; Wood G; Willemze R
Blood; 2011 Oct; 118(15):4024-35. PubMed ID: 21841159
[TBL] [Abstract][Full Text] [Related]
11. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.
Wada DA; Law ME; Hsi ED; Dicaudo DJ; Ma L; Lim MS; Souza Ad; Comfere NI; Weenig RH; Macon WR; Erickson LA; Ozsan N; Ansell SM; Dogan A; Feldman AL
Mod Pathol; 2011 Apr; 24(4):596-605. PubMed ID: 21169992
[TBL] [Abstract][Full Text] [Related]
12. CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L; Zain J; Rosen ST; Querfeld C
Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
[TBL] [Abstract][Full Text] [Related]
13. Novel use of 308-nm excimer laser to treat a primary cutaneous CD30+ lymphoproliferative nodule.
Meisenheimer JL
J Drugs Dermatol; 2007 Apr; 6(4):440-2. PubMed ID: 17668543
[TBL] [Abstract][Full Text] [Related]
14. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.
Wieser I; Oh CW; Talpur R; Duvic M
J Am Acad Dermatol; 2016 Jan; 74(1):59-67. PubMed ID: 26518172
[TBL] [Abstract][Full Text] [Related]
15. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
Querfeld C; Kuzel TM; Guitart J; Rosen ST
Oncology (Williston Park); 2007 May; 21(6):689-96; discussion 699-700,. PubMed ID: 17564326
[TBL] [Abstract][Full Text] [Related]
17. Intralymphatic Spread Is a Common Finding in Cutaneous CD30+ Lymphoproliferative Disorders.
Ferrara G; Ena L; Cota C; Cerroni L
Am J Surg Pathol; 2015 Nov; 39(11):1511-7. PubMed ID: 26371781
[TBL] [Abstract][Full Text] [Related]
18. Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders.
De Souza A; Tinguely M; Pfaltz M; Burghart DR; Kempf W
J Cutan Pathol; 2014 Dec; 41(12):901-6. PubMed ID: 25353265
[TBL] [Abstract][Full Text] [Related]
19. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
[TBL] [Abstract][Full Text] [Related]
20. Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by T-cell receptor gene rearrangement analysis: a case series of four patients and review of the literature.
Stowman AM; Hsia LL; Kanner WA; Mahadevan MS; Bullock GC; Patterson JW
Int J Dermatol; 2016 Feb; 55(2):e62-71. PubMed ID: 26266670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
